Mark S. Fineman, Ph.D., M.S., M.A.S.

 

Mark Fineman is the Senior Vice President, Clinical Development at Nuvie Bio. 

 

Mark is a clinical pharmacologist who led development at Glyscend Therapeutics, a venture-backed biotechnology company developing oral, gut-targeted polymer therapeutics for the treatment of chronic metabolic conditions. He is a recognized R&D leader who has more than 30 years of industry experience, including the leadership of teams through development, approval, and commercialization of three first-in-class diabetes medicines: Byetta  , the first GLP-1 agonist; Bydureon  , the first once-weekly GLP-1 agonist; and Symlin  , the first non-insulin treatment indicated for Type 1 diabetes. Mark also led the development of several early- and mid-stage programs in diabetes, obesity, osteoarthritis, neurodegenerative disease, psychiatric disease, lipodystrophy, and wound healing compounds.

 

Prior to his role at Glyscend, Mark was Senior Vice President, Clinical Affairs at Biosplice Therapeutics and Chief Scientific Officer at Elcelyx Therapeutics, where he led the development of minimally absorbed novel pharmaceutical and consumer products that target intestinal L cells to enhance secretion of gut hormones, including a program for the treatment of T2D patients with late-stage renal disease. Mark also held roles of increasing responsibility at Amylin for 20 years, including Executive Director of Medical Development and R&D Strategic Relations.

 

Mark received his Ph.D. in Medical Research from Vrije Universiteit, Amsterdam and his M.S. in Molecular Pathology and M.A.S. in Clinical Research from the University of California, San Diego.